R-GCVP regimen
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: Rituximab-Gemcitabine-Cyclophosphamide-Vincristine-Prednisone regimen
Overview
R-GCVP regimen refers to a regimen consisting of rituximab, gemcitabine, cyclophosphamide, vincristine (Oncovin), and prednisone used to treat both indolent and aggressive forms of diffuse large B-cell lymphoma.[1]
Regimen
RRituximab
GGemcitabine
CCyclophosphamide
VVincristine (Oncovin)
PPrednisone
Indications
References
- ↑ 1.0 1.1 Fields PA, Townsend W, Webb A, Counsell N, Pocock C, Smith P; et al. (2014). “De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial”. J Clin Oncol. 32 (4): 282–7. doi:10.1200/JCO.2013.49.7586. PMID 24220559.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH